Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy evaluation of nilotinib treatment in different genomic subtypes of gastrointestinal stromal tumors: A meta-analysis and systematic review.

Current problems in cancer - 1 Jun 2021

Zhao Zekun, Zhang Jie, Zhang Wenbing, Tan Siyuan, Wei Hao-Tang, You Jun, Guo Shanshan, Wang Jing, Chen Ping, Xu Yingying, Zong Liang

Abstract excerpt

Nilotinib has been used as a third-line drug for gastrointestinal stromal tumors (GISTs) after a failure of sunitinib. In this study, we aimed to evaluate the efficacy of nilotinib in different genomic subtypes of GISTs. We searched the English articles through EMBASE, Cochrane Library and PubMed Database regarding to the use of nilotinib on GISTs, which published up to February 15, 2019. Inclusion criteria were:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Treatment Outcome

Share to Young Adult

Source

Identifiers

PMID: 33495025
DOI: 10.1016/j.currproblcancer.2020.100705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy evaluation of nilotinib treatment in different genomic subtypes of gastrointestinal stromal tumors: A meta-analysis and systematic review.PMID 33495025Read ↗

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GISTSemantic proximity Read ↗

Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.Semantic proximity Read ↗

Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?Semantic proximity Read ↗

Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.Semantic proximity Read ↗

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.